Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Achieving a Graded Immune Response: BTK Adopts a Range of Active/Inactive Conformations Dictated by Multiple Interdomain Contacts.

Joseph RE, Wales TE, Fulton DB, Engen JR, Andreotti AH.

Structure. 2017 Oct 3;25(10):1481-1494.e4. doi: 10.1016/j.str.2017.07.014. Epub 2017 Aug 31.

PMID:
28867612
2.

SH3 domains: modules of protein-protein interactions.

Kurochkina N, Guha U.

Biophys Rev. 2013 Mar;5(1):29-39. doi: 10.1007/s12551-012-0081-z. Epub 2012 Jun 20. Review.

3.

ANKRD54 preferentially selects Bruton's Tyrosine Kinase (BTK) from a Human Src-Homology 3 (SH3) domain library.

Gustafsson MO, Mohammad DK, Ylösmäki E, Choi H, Shrestha S, Wang Q, Nore BF, Saksela K, Smith CI.

PLoS One. 2017 Apr 3;12(4):e0174909. doi: 10.1371/journal.pone.0174909. eCollection 2017.

4.

Receptor-guided 3D-QSAR studies, molecular dynamics simulation and free energy calculations of Btk kinase inhibitors.

Balasubramanian PK, Balupuri A, Kang HY, Cho SJ.

BMC Syst Biol. 2017 Mar 14;11(Suppl 2):6. doi: 10.1186/s12918-017-0385-5.

5.

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.

Fiorcari S, Maffei R, Audrito V, Martinelli S, Ten Hacken E, Zucchini P, Grisendi G, Potenza L, Luppi M, Burger JA, Deaglio S, Marasca R.

Oncotarget. 2016 Oct 4;7(40):65968-65981. doi: 10.18632/oncotarget.11782.

6.

Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.

Hamasy A, Wang Q, Blomberg KE, Mohammad DK, Yu L, Vihinen M, Berglöf A, Smith CI.

Leukemia. 2017 Jan;31(1):177-185. doi: 10.1038/leu.2016.153. Epub 2016 May 25.

7.

A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation.

Grassilli E, Pisano F, Cialdella A, Bonomo S, Missaglia C, Cerrito MG, Masiero L, Ianzano L, Giordano F, Cicirelli V, Narloch R, D'Amato F, Noli B, Ferri GL, Leone BE, Stanta G, Bonin S, Helin K, Giovannoni R, Lavitrano M.

Oncogene. 2016 Aug 18;35(33):4368-78. doi: 10.1038/onc.2015.504. Epub 2016 Jan 25.

8.

Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.

Bavi R, Kumar R, Choi L, Woo Lee K.

PLoS One. 2016 Jan 19;11(1):e0147190. doi: 10.1371/journal.pone.0147190. eCollection 2016.

9.

The Neutrophil Btk Signalosome Regulates Integrin Activation during Sterile Inflammation.

Volmering S, Block H, Boras M, Lowell CA, Zarbock A.

Immunity. 2016 Jan 19;44(1):73-87. doi: 10.1016/j.immuni.2015.11.011. Epub 2016 Jan 5.

10.

Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.

Rotin LE, Gronda M, MacLean N, Hurren R, Wang X, Lin FH, Wrana J, Datti A, Barber DL, Minden MD, Slassi M, Schimmer AD.

Oncotarget. 2016 Jan 19;7(3):2765-79. doi: 10.18632/oncotarget.6409.

11.

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.

Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ.

Clin Cancer Res. 2015 Jun 1;21(11):2538-45. doi: 10.1158/1078-0432.CCR-14-1462. Epub 2015 Mar 6.

12.

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate.

Wang Q, Vogan EM, Nocka LM, Rosen CE, Zorn JA, Harrison SC, Kuriyan J.

Elife. 2015 Feb 20;4. doi: 10.7554/eLife.06074.

13.

Splice-correction strategies for treatment of X-linked agammaglobulinemia.

Bestas B, Turunen JJ, Blomberg KE, Wang Q, Månsson R, El Andaloussi S, Berglöf A, Smith CI.

Curr Allergy Asthma Rep. 2015 Mar;15(3):510. doi: 10.1007/s11882-014-0510-0. Review.

14.

The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.

Loren CP, Aslan JE, Rigg RA, Nowak MS, Healy LD, Gruber A, Druker BJ, McCarty OJ.

Thromb Res. 2015 Jan;135(1):155-60. doi: 10.1016/j.thromres.2014.11.009. Epub 2014 Nov 18.

15.

Iterative tyrosine phosphorylation controls non-canonical domain utilization in Crk.

Sriram G, Jankowski W, Kasikara C, Reichman C, Saleh T, Nguyen KQ, Li J, Hornbeck P, Machida K, Liu T, Li H, Kalodimos CG, Birge RB.

Oncogene. 2015 Aug 6;34(32):4260-9. doi: 10.1038/onc.2014.361. Epub 2014 Nov 10.

16.

The autoinhibitory C-terminal SH2 domain of phospholipase C-γ2 stabilizes B cell receptor signalosome assembly.

Wang J, Sohn H, Sun G, Milner JD, Pierce SK.

Sci Signal. 2014 Sep 16;7(343):ra89. doi: 10.1126/scisignal.2005392.

17.

Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.

Drake JM, Lee JK, Witte ON.

Mol Cell Biol. 2014 May;34(10):1722-32. doi: 10.1128/MCB.01592-13. Epub 2014 Feb 24. Review.

18.

Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.

Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brown JR, Treon SP, Mitsiades CS, Griffin JD, Liu Q, Gray NS.

ACS Chem Biol. 2014 May 16;9(5):1086-91. doi: 10.1021/cb4008524. Epub 2014 Mar 17.

19.

Ibrutinib and novel BTK inhibitors in clinical development.

Akinleye A, Chen Y, Mukhi N, Song Y, Liu D.

J Hematol Oncol. 2013 Aug 19;6:59. doi: 10.1186/1756-8722-6-59. Review.

20.

Dual phosphorylation of Btk by Akt/protein kinase b provides docking for 14-3-3ζ, regulates shuttling, and attenuates both tonic and induced signaling in B cells.

Mohammad DK, Nore BF, Hussain A, Gustafsson MO, Mohamed AJ, Smith CI.

Mol Cell Biol. 2013 Aug;33(16):3214-26. doi: 10.1128/MCB.00247-13. Epub 2013 Jun 10.

Supplemental Content

Support Center